Geovax Labs Inc. (GOVX) Issues H1 2024 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
GeoVax Provides First Half 2024 Business Update
July 9, 2024 9:10 AM EDTAward of BARDA Project NextGen contract represents a significant milestone event;
total value of award to GeoVax and its CRO partner total approximately $367-388 million
BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVaxs
multi-antigen vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19
Progress across pipeline with planned data readouts in multiple trials expected during H2 2024
ATLANTA, GA - (NewMediaWire) - July 09, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today provided a business... More
